8-K
filed April 3, 2026, 7:59 PM ET
ticker DNLI
CIK 0001714899
other material
confidence high
sentiment neutral
materiality 0.70
Denali regains full rights to DNL593 after Takeda terminates collaboration
Denali Therapeutics Inc.
- Takeda terminated co-development agreement for DNL593 (PTV:PGRN) effective 60 days from April 3, 2026; reason is strategic, not safety/efficacy.
- Denali will continue Phase 1/2 study independently; results expected by end of 2026.
- Enrollment complete with 40 FTD-GRN participants; interim data showed dose-dependent CSF progranulin increases and favorable tolerability.
- Denali has no further financial obligations to Takeda post-termination and retains full intellectual property rights.
- DNL593 uses TransportVehicle platform, first FDA-approved BBB-crossing technology, addressing FTD-GRN with no approved slowing treatments.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001714899-26-000042
- form_type
- 8-K
- ticker
- DNLI
- cik
- 0001714899
- company_name
- Denali Therapeutics Inc.
- filed_at
- 2026-04-03T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:32.795377+00:00
- generated_at
- 2026-05-15T07:38:17.535943+00:00
- sec_items
- ["1.02", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.7
- calibrated_materiality_score
- 0.7
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001714899-26-000042
- json_url
- https://secwatch.observer/filing/0001714899-26-000042.json
- markdown_url
- https://secwatch.observer/filing/0001714899-26-000042.md
- text_url
- https://secwatch.observer/filing/0001714899-26-000042.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1714899/000171489926000042/0001714899-26-000042-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1714899/000171489926000042/dnli-20260403.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
BBDC
Barings BDC receives $67M cash from adviser, enters new $11M credit support for Sierra legacy investments
Barings BDC, Inc.
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 1.02, 9.01
same fact type: material_agreement
same SEC item: 1.02, 9.01
same event type: other_material
similar materiality
This filing
On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).
Comparable filing
Barings BDC, Inc. (the “Company”) and Barings LLC (the “Adviser”) entered into a new Credit Support Agreement (the “New CSA”). The New CSA provides similar credit support as previously provided under the Prior CSA for the remaining unrealized investments in two portfolio companies previously covered by the Prior CSA in an amount equal to the $10,994,928 fair value of such investments as of May 29, 2026 (the “Remaining Obligation”).
Filing page
SEC filing
SERV
Serve Robotics ends $150M ATM sales agreement, reports pro forma Q1 net loss of $51M from Diligent acquisition
Serve Robotics Inc. /DE/
May 11, 2026, 7:59 PM ET
other_material
Items 1.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.02, 9.01
same event type: other_material
similar materiality
This filing
On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).
Comparable filing
On May 7, 2026, Serve Robotics Inc. (the “Company”) and each of Cantor Fitzgerald & Co., Wedbush Securities Inc., Northland Securities, Inc., Ladenburg Thalmann & Co. Inc. and Seaport Global Securities LLC (collectively, the “Agents”) agreed to terminate the Controlled Equity Offering SM Agreement, dated as of March 6, 2025 (the “Prior Sales Agreement”).
Filing page
SEC filing
BBIO
BridgeBio Pharma establishes $500M at-the-market equity offering program
BridgeBio Pharma, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 1.02, 9.01
same fact type: material_agreement
same SEC item: 1.02, 9.01
same event type: other_material
similar materiality
This filing
On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).
Comparable filing
On May 7, 2026, in connection with entering into the Agreement, the Company agreed with Goldman Sachs and Leerink Partners (formerly known as SVB Securities LLC), to terminate that certain Equity Distribution Agreement, dated May 4, 2023, by and among the Company, Goldman Sachs and Leerink Partners, effective as of May 7, 2026.
Filing page
SEC filing
AVAI
AVAI Bio and Ainnova Tech mutually terminate JV agreement as of May 7, 2026
AVAI BIO, INC.
May 8, 2026, 7:59 PM ET
other_material
Items 1.02, 9.01
same fact type: material_agreement
same SEC item: 1.02, 9.01
same event type: other_material
similar materiality
This filing
On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).
Comparable filing
On May 7, 2026, Avai Bio, Inc., formerly known as Avant Technologies Inc. (the “Company” or “AVAI”), and Ainnova Tech Inc. (“Ainnova” or “AINN”) entered into a Mutual Termination Agreement (the “Termination Agreement”) to terminate, by mutual consent, the Joint Venture and License Agreement dated November 8, 2024 (effective as of November 11, 2024) (the “License Agreement”).
Filing page
SEC filing
XWIN
XMax raises $3.6M via private placement of 486,500 shares at $7.347/share
XMax Inc.
June 2, 2026, 4:30 PM ET
other_material
Items 1.01, 3.02, 9.01
same fact type: material_agreement
same SEC item: 9.01
same event type: other_material
similar materiality
This filing
On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).
Comparable filing
On May 28, 2026, XMax Inc. (the “ Company ”) entered into Securities Purchase Agreements (the “ Agreements ”) with certain non-U.S. investors identified on the signature pages thereto (the “ Purchasers ”), pursuant to which the Company agreed to sell to the Purchasers in a private placement for a total of 486,500 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $7.347 per share for an aggregate offering price of $3,574,315.50 (the “ Private Placement ”).
Filing page
SEC filing
CNL Strategic Capital, LLC
Shareholders reject enhanced liquidity plan (25% repurchase); loan amended for equity buybacks
CNL Strategic Capital, LLC
June 2, 2026, 4:04 PM ET
other_material
Items 1.01, 2.03, 5.07, 8.01, 9.01
same fact type: material_agreement
same SEC item: 9.01
same event type: other_material
similar materiality
This filing
On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).
Comparable filing
On May 29, 2026, CNL Strategic Capital B, Inc. (the “Borrower”), a wholly-owned subsidiary of CNL Strategic Capital, LLC (the “Company”), and Valley National Bank, a Tennessee banking corporation (referred to as “Valley National Bank”), entered into a Third Amendment (the “Third Amendment”) to the Loan and Security Agreement, as amended (the “Loan Agreement”), previously entered into by such parties for a $50.0 million revolving line of credit (the “Line of Credit”).
Filing page
SEC filing
OSRH
OSR Holdings enters $30M asset purchase agreement with subsidiary Vaximm for VXM01 IP
OSR Holdings, Inc.
June 2, 2026, 1:16 PM ET
other_material
Items 1.01, 9.01
same fact type: material_agreement
same SEC item: 9.01
same event type: other_material
similar materiality
This filing
On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).
Comparable filing
On May 27, 2026, OSR Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Vaximm AG (“Vaximm”), a clinical-stage biopharmaceutical company organized under the laws of Switzerland.
Filing page
SEC filing
VTIX
Virtuix amends warrants to $4.00 exercise price, extends period to July 27, 2026
Virtuix Holdings Inc.
June 2, 2026, 9:15 AM ET
other_material
Items 1.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 9.01
same event type: other_material
similar materiality
This filing
On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).
Comparable filing
On June 1, 2026, Virtuix Holdings Inc. (the “Company”) entered into amendments to each of the following warrants to purchase shares of Class A Common Stock (collectively, the “Warrant Amendments”) with Streeterville Capital, LLC (the “Investor”) amending the exercise price and extending the Reduced Exercise Price Period (as defined below) to each such warrant
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.